LYCOV1404 bebtelovimab
Ended Definitive Contract Awarded Last action
- Contract number
- W58P0522C0012
- Awardee
-
ELI Lilly And Company UEI UHHVNTY54K68
- Awarding agency
-
ACC Aberdeen Proving Ground
Army Contracting Command, Department of Defense
- Obligated
- $1,463,250,000
Award facts
- Contract value 70% obligated
-
- $1,463,250,000.00 Current, with exercised options
- $2,105,000,000.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- Indianapolis, IN 46285, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $109,500,000 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $273,750,000 | |
| Original award | $1,080,000,000 |
About this award
This is a definitive contract awarded by the Joint PEO Chemical and Biological Defense, a component of the Department of the Army Acquisition Support Center, to Eli Lilly and Company, a for-profit manufacturer of goods. The $2,105,000,000.00 firm fixed price contract is for the delivery of LYCOV1404 BEBTELOVIMAB, a monoclonal antibody treatment, to support the government's Coronavirus COVID-19 response efforts. The contract has an ultimate completion date of September 30, 2023 and does not have a set-aside designation. Eli Lilly and Company has previously received over $5 billion in prime federal contracts from the same agency to supply other monoclonal antibody products such as LY-COV555 and LY-COV016. The company also holds a $2.4 billion single award indefinite delivery contract with the agency, under which over $1.8 billion in orders have been placed to date for combination monoclonal antibody treatments.
Quick answers
Who was awarded contract W58P0522C0012?
W58P0522C0012 was awarded to ELI Lilly And Company by ACC Aberdeen Proving Ground (Army Contracting Command) on February 10, 2022.
How much is contract W58P0522C0012 worth?
The government has obligated $1,463,250,000 on W58P0522C0012. Its potential value, with all options, is $2,105,000,000.
Which agency awarded contract W58P0522C0012?
ACC Aberdeen Proving Ground (Army Contracting Command) awarded W58P0522C0012, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).
Was contract W58P0522C0012 competed?
The extent of competition for W58P0522C0012 was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award